The latest updates on our research and how it is improving people’s lives.
1 March 2024
The Medical Research Council’s Infections and Immunity Board (IIB) funds research into infectious human disease and disorders of the human immune system.
23 February 2024
ZEISS is partnering with the University of Oxford bringing ground-breaking microscopy imaging equipment, and analysis tools, to advance the study of global health and disease.
22 February 2024
Rapid advances in Artificial Intelligence (AI) have opened the way for the creation of a huge range of new healthcare tools, but to ensure that these tools do not exacerbate preexisting health inequities, researchers urge the use of more representative data in their development.
19 February 2024
NDORMS researchers have identified how cells work to resolve frozen shoulder, opening up potential new targets for treatment and reducing the need for surgery.
5 February 2024
A team at NDORMS has developed a new approach to significantly improve the accuracy of RNA sequencing. They pinpoint the primary source of inaccurate quantification in both short and long-read RNA sequencing, and have introduced the concept of “majority vote” error correction leading to a substantial improvement in RNA molecular counting.
29 January 2024
A training course on Principles of Management for Delayed Presenting Clubfoot (DPC) took place 11-12th December 2023 at CURE Children’s Hospital of Ethiopia, Addis Ababa.
24 January 2024
Published in PLOS, the new guideline will help the scientific community to write complete and transparent research reports involving consensus methods.
18 January 2024
NDORMS welcomed a delegation of medical researchers from Taipei Medical University this week to exchange research ideas and for potential future collaborations.
17 January 2024
The Oxford Experimental Medicine Clinical Research Facility (EMCRF) at NDORMS has received its first volunteers as part of the LEGACY03 trial to improve vaccine design for different age groups.
12 January 2024
A recent study has revealed the effectiveness of COVID-19 vaccines in preventing long COVID.
Patients can interrupt treatment of immune-supressing medicines for two-weeks in order to boost immunity provided by COVID-19 booster vaccine, finds major study
14 December 2023
A major clinical trial, led by the University of Nottigham and managed by the Oxford Clinical trials Research Unit (OCTRU), has shown that people with inflammatory conditions are able to improve the antibody response from a COVID-19 booster vaccination by interrupting their treatment for two weeks immediately after having the vaccine.
8 December 2023
Four researchers at NDORMS have been awarded a Research Ignition Award, as part of an initiative by the Kennedy Trust for Rheumatology to stimulate new and ambitious avenues of research.
Professor Chris Lavy awarded honorary fellowship from the College of Surgeons of East, Central and Southern Africa
7 December 2023
Professor Chris Lavy has been awarded an honorary fellowship by the College of Surgeons of East Central and Southern Africa (COSECSA).
Kennedy Trust gift to help drive forward research into inflammatory and musculoskeletal diseases at Oxford
30 November 2023
Two professorships in translational medicine have been endowed at the Kennedy Institute of Rheumatology thanks to a generous gift from the Kennedy Trust for Rheumatology Research.
New discovery furthers our understanding of how critical immune cells are controlled during an infection
21 November 2023
A recent publication from Audrey Gérard’s lab looks at how a specific protein, called IFNγ, can coordinate CD8+ T cell responses during a flu infection.
31 October 2023
The annual Oxford Myeloma Workshop brings together experts in myeloma research, clinical care, patient advocates and industry representatives, to help international efforts to improve patient lives affected by multiple myeloma. Multiple myeloma is the second most common among all blood cancers, is currently incurable and puts massive strains on patient quality of life with a significantly higher proportion (10 fold) share in health care costs.